You just read:

Celator® Pharmaceuticals Announces Positive Results Demonstrating Reduced Healthcare Resource Use with VYXEOSTM Compared to Standard Treatment for Acute Myeloid Leukemia (AML)

News provided by

Celator Pharmaceuticals, Inc.

25 Apr, 2016, 07:00 ET